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Abstract
Background
The inflammatory bowel diseases (IBD), Crohn’s disease (CD) and ulcerative colitis (UC),
result from the combined effects of susceptibility genes and environmental factors. Previous
studies have shown that polymorphisms in the Toll-like receptor (TLR), the apoptosis, the
IL-23/IL-17 and the interferon gamma (IFNG) pathways are associated with risk of both CD
and UC.
Methods
Using a candidate gene approach, 21 functional single nucleotide polymorphisms (SNPs)
in 15 genes were assessed in a clinical homogeneous group of severely diseased ethnic
Danish patients consisting of 624 patients with CD, 411 patients with UC and 795 controls.
The results were analysed using logistic regression.
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Results
The polymorphisms TLR5 (rs5744174) and IL12B (rs6887695) were associated with risk of
CD, and TLR1 (rs4833095) and IL18 (rs187238) were associated with risk of both CD and
UC (p<0.05). After Bonferroni correction for multiple testing, the homozygous variant geno-
type of TLR1 743 T>C (rs4833095) was associated with increased risk CD (OR: 3.15, 95%
CI: 1.59–6.26, p = 0.02) and CD and UC combined (OR: 2.96, 95% CI: 1.64–5.32, p =
0.005).
Conclusion
Our results suggest that genetically determined high activity of TLR1 and TLR5 was associ-
ated with increased risk of both CD and UC and CD, respectively. This supports that the
host microbial composition or environmental factors in the gut are involved in risk of IBD.
Furthermore, genetically determined high activity of the IL-23/IL-17 pathway was associ-
ated with increased risk of CD and UC. Overall, our results support that genetically deter-
mined high inflammatory response was associated with increased risk of both CD and UC.
Introduction
Chronic inflammatory bowel diseases (IBD), Crohn’s disease (CD) and ulcerative colitis (UC),
are complex diseases that result from the interaction of numerous genetic and environmental
factors [1]. Genetic association studies have identified polymorphisms in the Toll-like receptor
(TLR) [2,3], the apoptosis [4–6], the IL-23/IL-17 [4–6] and the interferon gamma (IFNG) [4–
6] pathways associated with susceptibility of CD and UC. As described below the inflamma-
some is connected to all of these pathways and it could be speculated that polymorphisms in
the inflammasome pathway could be associated with CD or UC.
These pathways are involved in the autoimmune response to Pathogen-Associated Molecu-
lar Patterns (PAMPs) such as bacterial or viral DNA, flagellin or lipopolysaccharide (LPS).
PAMPs can be bound by the membrane bound TLRs and induce inflammation by activating a
number of pro- and anti-inflammatory cytokines [7]. PAMPs can also be recognized by Nod-
like receptors (NLRs), which are intracellular receptors. NLRP1 and NLRP3 are members of
the inflammasome protein complexes, which can activate the pro-protein caspase-1. The acti-
vation of caspase-1 can be suppressed by CARD8 [8]. Caspase-1 activates the pro-inflamma-
tory cytokines IL-1β and IL-18, which are synthesized as pro-proteins [9]. In turn, IL-1β and
IL-18 can induce the production of IL-17 [10].
NLRP1, NLRP3 and CARD8 have also been described to be involved in the apoptotic path-
way, where overexpression of NLRP1 and NLRP3 stimulates apoptosis through activation of
caspases [11,12] and CARD8 inhibit apoptosis by inhibiting the activation of caspase-1 [13].
In the IL-23/IL-17 pathway, IL-23 enhances the secretion of the pro-inflammatory cytokine
IL-17, which in turn enhances the production of pro-inflammatory mediators such as IL-1β,
IL-6, IL-8 and TNF-α [14]. IL-23 is a heterodimer composed of IL-12p40 and IL-23p19. IL-
12p40 also acts as a subunit of the IL-12p35/IL-12p40 heterodimer cytokine IL-12. IL-12 can
act pro-inflammatory by activating IFN-γ and anti-inflammatory by activating the anti-inflam-
matory cytokine IL-10 [15] and by inhibiting the pro-inflammatory cytokine IL-17 [14]. The
IL-12 and IL-23 pathways also share the receptor subunit IL12R-β1, which is part of the IL12
receptor (IL12R-β1/IL12R-β2) and IL23 receptor (IL12R-β1/IL23R) heterodimer complex. The
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signalling through the IL12 and IL23 receptor also share intracellular mechanisms, where both
receptors bind the Jak2 kinase, which in turn activates the STAT4 transcription factor. How-
ever, the resulting DNA binding STAT transcription complexes differ and involve the STAT3/
STAT4 heterodimer in IL23 signalling rather than the STAT4 homodimer in IL12 signalling
[14].
IL-18, which can be activated by the inflammasome, can feedback activate the synthesis of
IFN-γ. IFN-γ binds to the membrane bound IFNG receptor which is comprised of two ligand-
binding IFNGR1 chains and two signal-transducing IFNGR2 chains. Binding of IFN-γ to the
IFNG receptor recruits the Jak2 kinase. Jak2 initiates a kinase cascade, which ultimately acti-
vates the transcription factor STAT1 [16]. Another important activator of IFN-γ is the tran-
scription factor T-bet (TBX21) [17].
In this study, we wanted to investigate whether functional single nucleotide polymorphisms
(SNPs) in genes involved in the Toll-like receptor (TLR1, TLR5 and TIRAP), the inflamma-
some or apoptotic (NLRP1, NLRP3 and CARD8), the IL-23/IL-17 (IL12B, IL12RB1, IL12RB2,
IL17A, IL18 and JAK2) and the IFNG (IFNGR1, IFNGR2 and TBX21) pathways were associated
with risk of CD or UC in a Danish cohort of severely diseased patients. Knowing the biological
effects of the studied polymorphisms allows a biological interpretation of the associations
based on increased or decreased gene activity [3,18,19].
Materials and Methods
Cohort
As described by Bank et al. an ethnic Danish cohort consisting of 624 patients with CD and
411 patients with UC was established [3]. The patients either received or were considered can-
didates to anti-tumor necrosis factor-α (anti-TNF) therapy (infliximab or adalimumab) and
were thus considered to be a homogenous group of moderately to severely ill IBD patients. The
control group consisted of 795 healthy blood donors recruited from Viborg, Denmark [20].
Genotyping
For the patients, DNA was extracted from cryopreserved blood clots by using the Maxwell 16
Blood purification kit (Promega, Madison, Wisconsin, USA) according to the manufacture-
rs`instructions [21]. For the healthy controls, DNA was extracted from EDTA-stabilized
peripheral blood by either PureGene (Qiagen, Hilden, Germany) or Wizard Genomic (Pro-
mega, Madison, Wisconsin, USA) DNA purification kit according to the manufacturers`in-
structions [20]. Competitive Allele-Specific Polymerase chain reaction (KASP™), an end-point
PCR technology, was used by LGC Genomics for genotyping (LGC Genomics, Hoddesdon,
United Kingdom) (http://www.lgcgenomics.com/).
The SNPs studied were TLR1 (rs4833095), TLR5 (rs5744174 and rs2072493), TIRAP
(rs8177374), CARD8 (rs2043211), NLRP1 (rs878329 and rs2670660), NLRP3 (rs10754558),
IL12B (rs3212217 and rs6887695), IL12RB1 (rs401502), IL12RB2 (rs11810249), IL17A
(rs8193036), IL18 (rs1946518 and rs187238), IFNGR1 (rs2234711), IFNGR2 (rs8134145,
rs8126756 and rs17882748), TBX21 (rs17250932) and JAK2 (rs12343867).
Genotyping of TLR5 (rs2072493), IFNGR2 (rs8134145) and IL17A (rs8193036) failed. The
18 SNPs were replicated in 94 randomly selected samples yielding>99% identical genotypes.
The studied SNPs had minor allele frequencies of 0.09 to 0.50.
Linkage disequilibrium for the assessed SNPs in the same gene was calculated using the SNP
Annotation and Proxy Search (SNAP) software [22]. In addition, linkage disequilibrium
between the assessed SNPs in our study and known susceptibility loci in the same gene was
calculated.
SNPs Associated with Risk of CD or UC
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Power calculations
The Genetic Power Calculator was utilized for power analysis of discrete traits [23]. The lowest
minor allele frequency (MAF) of the studied SNPs was 0.14. The ‘high-risk allele frequency’
was set to 0.14, the ‘prevalence’ was set to 0.00241 (CD), 0.00263 (UC) and 0.00504 (IBD) [24],
D-prime was set to 1, type I error rate was set to 0.05 and number of cases and control:case
ratio was based on Table 1. This cohort study had more than 80% chance of detecting a domi-
nant effect with an odds ratio (OR) of 1.4 for CD, 1.5 for UC and 1.4 for IBD.
Statistical analysis
Logistic regression was used to compare genotype distributions among patients with CD, UC
and IBD versus healthy controls. Odds ratio adjusted for age and gender were assessed
(Table 2). Odds ratio unadjusted (crude) and adjusted for age, gender and smoking status were
included as supplementary Tables (S2 and S3 Tables). A chi-square test was used to test for
deviation from Hardy-Weinberg equilibrium among the healthy controls.
Statistical analyses were performed using STATA version 11 (STATA Corp., Texas, USA).
Ethics Statement
The study was conducted in accordance with the Declaration of Helsinki and was approved by
the Regional Ethics Committees of Central (M20100153) and Southern (S-20120113) Denmark
and the Danish Data Protection Agency of Central (RM: J. 2010-41-4719) and Southern (RSD:
2008-58-035) Denmark. The Ethics Committees gave suspension for obtaining written
informed consent.
Results
Study population
Characteristics of the Danish patients with CD, UC and healthy controls are shown in Table 1.
The genotype distributions among the healthy controls deviated from Hardy-Weinberg equi-
librium for TLR1 743 T>C (rs4833095) (p = 0.03). After correction for multiple testing, all
SNPs studied were in Hardy-Weinberg equilibrium.
Polymorphisms associated with risk of CD
The homozygous variant genotype of TLR1 743 T>C (rs4833095) (OR: 3.15, 95% confidence
interval (CI): 1.59–6.26, p = 0.001) and TLR5 936 T>C (rs5744174) (OR: 1.54, 95% CI: 1.04–
2.28, p = 0.03) and the combined homozygous and the heterozygous variant genotypes of
IL12B G>C (rs6887695) (OR: 1.49, 95% CI: 1.13–1.96, p = 0.004) were associated with
increased risk of CD. The homozygous variant genotype of IL18–137 G>C (rs187238) (OR:
0.50, 95% CI: 0.28–0.88, p = 0.02) was associated with reduced risk of CD (Table 2).
After Bonferroni correction for multiple testing, the homozygous variant genotype of TLR1
743 T>C (rs4833095) (OR: 3.15, 95% CI: 1.59–6.26, p = 0.02) was associated with increased
risk of CD.
Polymorphisms associated with risk of UC
The homozygous variant genotype of TLR1 743 T>C (rs4833095) (OR: 2.92, 95% CI: 1.42–
6.00, p = 0.004) was associated with increased risk of UC. The combined homozygous and the
heterozygous variant genotypes of IL18–137 G>C (rs187238) (OR: 0.72, 95% CI: 0.54–0.97,
p = 0.03) were associated with reduced risk of UC (Table 2).
SNPs Associated with Risk of CD or UC
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Polymorphisms associated with risk of IBD
In order to increase statistical power the analyses for CD and UC were combined (IBD). The
studied polymorphisms generally showed the same direction of effect for CD and UC
(Table 2).
The homozygous variant genotype of TLR1 743 T>C (rs4833095) (OR: 2.96, 95% CI: 1.64–
5.32, p = 0.0003) and the combined homozygous and the heterozygous variant genotypes of
IL12B G>C (rs6887695) (OR: 1.29, 95% CI: 1.03–1.62, p = 0.03) were associated with increased
risk of IBD. The homozygous variant genotype of IL18–137 G>C (rs187238) (OR: 0.61, 95%
CI: 0.39–0.95, p = 0.03) was associated with reduced risk of IBD (Table 2).
After Bonferroni correction for multiple testing, the homozygous variant genotype of TLR1
743 T>C (rs4833095) (OR: 2.96, 95% CI: 1.64–5.32, p = 0.005) was associated with increased
risk of IBD.
The biologic effects of the studied SNPs and OR for polymorphisms which have been
shown to be associated with risk of CD, UC or IBD in other studies and in this study were sum-
marized in S1 Table.
Linkage disequilibrium
Rs6887695 (IL12B) included in this study was in linkage disequilibrium with rs6556412
(IL12B) associated with CD in another study with r2 = 0.96 and D' = 1.00. No linkage disequi-
librium was found for the SNPs in TLR5 (rs5744174 and rs2072493), NLRP1 (rs878329 and
Table 1. Description of the study participants.
Crohns Disease (CD) Ulcerative Colitis (UC) Controls
(n = 624) (n = 411) (n = 795)
Gender: n (%)
Male 272 (44) 201 (49) 411 (52)
Female 352 (56) 210 (51) 384 (48)
Age:
Median (5%-95%) 37 (20–67) 42 (20–72) 43 (23–60)
Age at diagnosis:
Median (5%-95%) 25 (14–59) 33 (15–67) -
Smoking habits: n (%)
Smokers 178 (29) 30 (7) 207 (26)
Former smokers 64 (10) 86 (21) 392 (49)
Never smokers 156 (25) 102 (25) 189 (24)
Data not available 226 (36) 193 (47) 7 (1)
Location UC: n (%)
Proctitis (E1) - 53 (13) -
Left side (E2) - 183 (45) -
Extensive (E3) - 134 (33) -
Data not available - 41 (10) -
Location CD: n (%)
Colonic (L2) 208 (33) - -
Ileal (L1) 172 (28) - -
Ileocolonic (L3) 210 (34) - -
Data not available 34 (5) - -
doi:10.1371/journal.pone.0145302.t001
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Table 2. Odds ratios (OR) (adjusted for age and sex) for genotypes studied among healthy controls and patients with Crohns disease (CD), ulcera-
tive colitis (UC) and combined inflammatory bowel disease (IBD).
Crohns disease (CD) 1 Ulcerative colitis (UC)1 Inﬂammatory bowel disease (IBD)1
Gene (rs-
number)
NCD NUC NControl OR
(95%
CI)
p-
value
Bonferroni
corrected p-
value
OR
(95%
CI)
p-
value
Bonferroni
corrected p-
value
OR
(95%
CI)
p-
value
Bonferroni
corrected p-
value
TLR1 (rs4833095), MAF: 0.20
TT 381 236 485
TC 198 146 261 0.90
(0.67–
1.20)
0.47 1.00 1.11
(0.82–
1.51)
0.51 1.00 0.96
(0.76–
1.22)
0.74 1.00
CC 41 25 20 3.15
(1.59–
6.26)
0.001 0.02 2.92
(1.42–
6.00)
0.004 0.07 2.96
(1.64–
5.32)
0.0003 0.005
TC or
CC
239 171 281 1.04
(0.78–
1.37)
0.80 1.00 1.23
(0.92–
1.65)
0.17 1.00 1.09
(0.87–
1.37)
0.46 1.00
TLR5 (rs5744174), MAF: 0.45
TT 186 123 215
TC 295 191 399 0.96
(0.70–
1.33)
0.82 1.00 0.92
(0.66–
1.30)
0.65 1.00 0.96
(0.73–
1.25)
0.74 1.00
CC 141 95 144 1.54
(1.04–
2.28)
0.03 0.63 1.24
(0.82–
1.88)
0.30 1.00 1.36
(0.98–
1.88)
0.07 1.00
TC or
CC
436 286 543 1.10
(0.81–
1.49)
0.54 1.00 1.01
(0.73–
1.39)
0.96 1.00 1.06
(0.82–
1.36)
0.65 1.00
TIRAP (rs8177374), MAF: 0.15
CC 457 301 556
CT 146 97 185 1.08
(0.79–
1.48)
0.63 1.00 1.00
(0.72–
1.41)
0.98 1.00 1.04
(0.80–
1.36)
0.75 1.00
TT 16 8 21 0.86
(0.36–
2.05)
0.73 1.00 0.68
(0.26–
1.77)
0.43 1.00 0.74
(0.36–
1.53)
0.42 1.00
CT or TT 162 105 206 1.06
(0.78–
1.43)
0.71 1.00 0.97
(0.70–
1.34)
0.84 1.00 1.01
(0.79–
1.30)
0.93 1.00
CARD8 (rs2043211), MAF: 0.35
AA 305 182 321
AT 246 175 342 0.80
(0.60–
1.07)
0.13 1.00 0.94
(0.69–
1.28)
0.69 1.00 0.82
(0.65–
1.05)
0.11 1.00
TT 70 54 94 0.77
(0.50–
1.20)
0.25 1.00 1.06
(0.68–
1.65)
0.78 1.00 0.91
(0.64–
1.30)
0.60 1.00
AT or TT 316 229 436 0.79
(0.61–
1.04)
0.09 1.00 0.97
(0.73–
1.29)
0.83 1.00 0.84
(0.67–
1.06)
0.14 1.00
NLRP1 (rs878329), MAF: 0.46
GG 181 137 217
GC 316 181 394 0.98
(0.72–
1.35)
0.91 1.00 0.78
(0.56–
1.09)
0.15 1.00 0.89
(0.68–
1.15)
0.37 1.00
(Continued)
SNPs Associated with Risk of CD or UC
PLOSONE | DOI:10.1371/journal.pone.0145302 December 23, 2015 6 / 14
Table 2. (Continued)
Crohns disease (CD) 1 Ulcerative colitis (UC)1 Inﬂammatory bowel disease (IBD)1
Gene (rs-
number)
NCD NUC NControl OR
(95%
CI)
p-
value
Bonferroni
corrected p-
value
OR
(95%
CI)
p-
value
Bonferroni
corrected p-
value
OR
(95%
CI)
p-
value
Bonferroni
corrected p-
value
CC 122 91 155 0.87
(0.59–
1.28)
0.47 1.00 1.03
(0.69–
1.54)
0.89 1.00 1.00
(0.73–
1.38)
0.99 1.00
GC or
CC
438 272 549 0.95
(0.70–
1.28)
0.72 1.00 0.85
(0.63–
1.16)
0.32 1.00 0.92
(0.72–
1.18)
0.51 1.00
NLRP1 (rs2670660), MAF: 0.46
AA 181 127 222
AG 312 195 390 1.01
(0.74–
1.39)
0.93 1.00 0.91
(0.65–
1.27)
0.58 1.00 0.96
(0.74–
1.24)
0.75 1.00
GG 128 87 154 0.92
(0.62–
1.35)
0.65 1.00 1.05
(0.70–
1.59)
0.80 1.00 1.03
(0.74–
1.42)
0.87 1.00
AG or
GG
440 282 544 0.98
(0.73–
1.32)
0.91 1.00 0.95
(0.70–
1.30)
0.75 1.00 0.98
(0.77–
1.25)
0.86 1.00
NLRP3 (rs10754558), MAF: 0.38
CC 225 149 294
CG 307 202 355 1.02
(0.76–
1.37)
0.92 1.00 1.12
(0.82–
1.53)
0.48 1.00 1.09
(0.85–
1.39)
0.51 1.00
GG 84 58 111 0.95
(0.63–
1.43)
0.80 1.00 1.14
(0.74–
1.77)
0.55 1.00 1.08
(0.77–
1.52)
0.66 1.00
CG or
GG
391 260 466 1.00
(0.76–
1.32)
0.99 1.00 1.13
(0.84–
1.52)
0.44 1.00 1.08
(0.86–
1.37)
0.50 1.00
IL12B (rs3212217), MAF: 0.19
GG 402 287 499
GC 194 106 235 0.89
(0.66–
1.20)
0.44 1.00 0.77
(0.56–
1.07)
0.12 1.00 0.81
(0.63–
1.04)
0.10 1.00
CC 25 12 25 1.70
(0.82–
3.51)
0.16 1.00 1.07
(0.46–
2.50)
0.87 1.00 1.37
(0.73–
2.56)
0.33 1.00
GC or
CC
219 118 260 0.95
(0.72–
1.26)
0.72 1.00 0.80
(0.58–
1.09)
0.15 1.00 0.86
(0.67–
1.09)
0.20 1.00
IL12B (rs6887695), MAF: 0.29
GG 261 199 385
GC 283 169 293 1.50
(1.12–
2.00)
0.006 0.11 1.20
(0.88–
1.64)
0.24 1.00 1.29
(1.01–
1.64)
0.04 0.72
CC 71 39 72 1.45
(0.91–
2.30)
0.11 1.00 1.19
(0.71–
1.98)
0.51 1.00 1.29
(0.88–
1.90)
0.20 1.00
GC or
CC
354 208 365 1.49
(1.13–
1.96)
0.004 0.08 1.20
(0.90–
1.61)
0.22 1.00 1.29
(1.03–
1.62)
0.03 0.52
(Continued)
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Table 2. (Continued)
Crohns disease (CD) 1 Ulcerative colitis (UC)1 Inﬂammatory bowel disease (IBD)1
Gene (rs-
number)
NCD NUC NControl OR
(95%
CI)
p-
value
Bonferroni
corrected p-
value
OR
(95%
CI)
p-
value
Bonferroni
corrected p-
value
OR
(95%
CI)
p-
value
Bonferroni
corrected p-
value
IL12RB1 (rs401502), MAF: 0.32
CC 287 178 360
CG 266 191 303 1.08
(0.81–
1.44)
0.61 1.00 1.32
(0.97–
1.78)
0.08 1.00 1.24
(0.98–
1.58)
0.07 1.00
GG 67 39 87 0.92
(0.59–
1.43)
0.70 1.00 0.93
(0.56–
1.54)
0.78 1.00 0.91
(0.63–
1.33)
0.64 1.00
CG or
GG
333 230 390 1.04
(0.79–
1.36)
0.78 1.00 1.23
(0.92–
1.64)
0.16 1.00 1.17
(0.93–
1.46)
0.18 1.00
IL12RB2 (rs11810249), MAF: 0.00
CC 622 408 774
CT 1 2 0 1.00
(1.00–
1.00)
1.00 1.00 1.00
(1.00–
1.00)
1.00 1.00 1.00
(1.00–
1.00)
1.00 1.00
TT 0 0 0 1.00
(1.00–
1.00)
1.00 1.00 1.00
(1.00–
1.00)
1.00 1.00 1.00
(1.00–
1.00)
1.00 1.00
CT or TT 1 2 0 1.00
(1.00–
1.00)
1.00 1.00 1.00
(1.00–
1.00)
1.00 1.00 1.00
(1.00–
1.00)
1.00 1.00
IL18 (rs1946518), MAF: 0.39
GG 236 148 282
GT 299 201 363 1.03
(0.77–
1.39)
0.84 1.00 1.05
(0.76–
1.43)
0.78 1.00 1.05
(0.82–
1.34)
0.68 1.00
TT 83 57 113 0.72
(0.47–
1.11)
0.14 1.00 0.95
(0.61–
1.49)
0.83 1.00 0.84
(0.59–
1.19)
0.33 1.00
GT or
TT
382 258 476 0.95
(0.72–
1.26)
0.73 1.00 1.02
(0.76–
1.38)
0.88 1.00 1.00
(0.79–
1.26)
1.00 1.00
IL18 (rs187238), MAF: 0.29
GG 334 231 387
GC 246 144 312 0.93
(0.70–
1.23)
0.60 1.00 0.72
(0.53–
0.98)
0.04 0.71 0.87
(0.69–
1.11)
0.26 1.00
CC 36 32 64 0.50
(0.28–
0.88)
0.02 0.31 0.73
(0.42–
1.27)
0.26 1.00 0.61
(0.39–
0.95)
0.03 0.57
GC or
CC
282 176 376 0.85
(0.65–
1.12)
0.26 1.00 0.72
(0.54–
0.97)
0.03 0.54 0.83
(0.66–
1.04)
0.10 1.00
IFNGR1 (rs2234711), MAF: 0.39
TT 235 158 290
TC 276 196 361 0.89
(0.66–
1.20)
0.44 1.00 1.18
(0.86–
1.60)
0.31 1.00 1.03
(0.80–
1.31)
0.83 1.00
(Continued)
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Table 2. (Continued)
Crohns disease (CD) 1 Ulcerative colitis (UC)1 Inﬂammatory bowel disease (IBD)1
Gene (rs-
number)
NCD NUC NControl OR
(95%
CI)
p-
value
Bonferroni
corrected p-
value
OR
(95%
CI)
p-
value
Bonferroni
corrected p-
value
OR
(95%
CI)
p-
value
Bonferroni
corrected p-
value
CC 104 54 119 1.36
(0.91–
2.02)
0.13 1.00 0.84
(0.52–
1.34)
0.47 1.00 1.14
(0.81–
1.60)
0.46 1.00
TC or
CC
380 250 480 0.99
(0.75–
1.32)
0.97 1.00 1.10
(0.81–
1.48)
0.54 1.00 1.05
(0.84–
1.33)
0.67 1.00
IFNGR2 (rs8126756), MAF: 0.14
TT 465 289 553
TC 134 112 168 1.18
(0.85–
1.64)
0.32 1.00 1.28
(0.91–
1.79)
0.15 1.00 1.24
(0.94–
1.62)
0.12 1.00
CC 13 3 18 0.67
(0.27–
1.67)
0.39 1.00 0.33
(0.08–
1.34)
0.12 1.00 0.55
(0.24–
1.25)
0.15 1.00
TC or
CC
147 115 186 1.12
(0.82–
1.53)
0.49 1.00 1.18
(0.85–
1.64)
0.33 1.00 1.16
(0.89–
1.50)
0.27 1.00
IFNGR2 (rs17882748), MAF: 0.47
CC 180 113 199
CT 295 214 391 0.83
(0.60–
1.15)
0.26 1.00 0.98
(0.70–
1.39)
0.92 1.00 0.90
(0.69–
1.17)
0.43 1.00
TT 142 80 153 1.04
(0.71–
1.52)
0.86 1.00 0.92
(0.60–
1.40)
0.68 1.00 0.97
(0.70–
1.34)
0.86 1.00
CT or TT 437 294 544 0.89
(0.66–
1.21)
0.46 1.00 0.96
(0.69–
1.34)
0.82 1.00 0.92
(0.71–
1.18)
0.51 1.00
TBX21 (rs17250932), MAF: 0.18
TT 414 277 526
TC 187 124 210 1.20
(0.89–
1.61)
0.23 1.00 1.18
(0.86–
1.61)
0.31 1.00 1.21
(0.94–
1.55)
0.13 1.00
CC 18 10 32 0.62
(0.30–
1.31)
0.21 1.00 0.64
(0.29–
1.45)
0.29 1.00 0.65
(0.35–
1.19)
0.16 1.00
TC or
CC
205 134 242 1.11
(0.84–
1.48)
0.46 1.00 1.10
(0.82–
1.50)
0.52 1.00 1.13
(0.89–
1.43)
0.31 1.00
JAK2 (rs12343867), MAF: 0.28
TT 294 204 398
TC 264 166 299 1.19
(0.89–
1.58)
0.23 1.00 1.21
(0.90–
1.64)
0.21 1.00 1.21
(0.96–
1.54)
0.11 1.00
CC 56 40 61 1.30
(0.79–
2.14)
0.29 1.00 1.28
(0.75–
2.16)
0.37 1.00 1.33
(0.88–
2.01)
0.18 1.00
TC or
CC
320 206 360 1.21
(0.92–
1.59)
0.17 1.00 1.22
(0.92–
1.63)
0.17 1.00 1.23
(0.98–
1.54)
0.07 1.00
1Adjusted for age and sex. MAF: minor allele frequency.
doi:10.1371/journal.pone.0145302.t002
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rs2670660), IL12B (rs3212217 and rs6887695), IL18 (rs1946518 and rs187238) or IFNGR2
(rs8134145, rs8126756 and rs17882748) (r2< 0.8).
Discussion
In this Danish cohort of severely ill patients, 4 functional polymorphisms in 4 genes involved
in the Toll-like receptor (TLR1 and TLR5) and the IL-23/IL-17 (IL12B and IL18) pathways
were found to be associated with risk of CD or UC (Fig 1).
In agreement with our study, the variant allele of the IL12B G>C (rs6887695) polymor-
phism has been associated with increased risk of CD, in the Welcome Trust Case Control Con-
sortium and in a Japanese cohort [25,26]. Our study thereby confirms IL12B G>C (rs6887695)
as a susceptibility locus for CD. IL12B encode the IL-12p40 subunit which is part of both the
IL12 (IL-12p35/IL-12p40) and IL23 (IL-23p19/IL-12p40) heterodimers. All three subunits are
up-regulated in patients with CD [27–30]. Furthermore, IL12B G>C (rs6887695) is in linkage
disequilibrium with IL12B (rs6556412) which in another study has been associated with
increased risk of CD [5] in agreement with the results in our study for rs6887695. In addition,
the variant allele of IL12B G>C (rs6887695) has also been associated with increased risk of UC
in a meta-analysis (OR: 1.11), and although the direction of association was the same in our
study we were unable to confirm the result probably because of lack of power [31].
In contrast to our study, other case-control studies found opposite direction of association
in other ethnic groups of patients with UC for IL18–137 G>C (rs187238) [32] or opposite
direction of association in children with CD for TLR5 936 T>C (rs5744174) [33]. There is no
consensus of how the stop codon polymorphism in CARD8 A>T (rs2043211) influence risk of
CD [34,35].
To the best of our knowledge the polymorphism in TLR1 743 T>C (rs4833095) found to be
associated with both CD and UC in our study, has not previously been described as a suscepti-
bility polymorphism.
The biological interpretation of our results indicates that genetically determined high activ-
ity of TLR1 (rs4833095) was associated with increased risk of both CD and UC and genetically
determined high activity of TLR5 (rs5744174) was associated with increased risk of CD. Both
TLR1 and TLR5 can activate NFκB, a central regulator of inflammation regulating the expres-
sion of more than 150 genes including IL1B, IL12A (p35), IL12B (p40), IL17A, IL23A (p19)
and IFNG [36]. The associations found in TLR1 and TLR5 further supports that the host
microbial composition or environmental factors in the gut are involved in risk of IBD in agree-
ment with other studies [2,3].
The pro-protein IL-18 can be activated by the inflammasome and IL-18 can downstream
induce the production of the pro-inflammatory cytokine IL-17 [10]. In our study, the associa-
tions found for the polymorphism -137 G>C (rs187238) indicates that genetically determined
low activity of IL-18 was associated with reduced risk of CD and UC. This suggests that lower
activity of the IL-23/IL-17 pathway was associated with reduced risk of CD and UC.
The activity of IL-17 can also be up-regulated through the IL-23 pathway and down-regu-
lated through the IL-12 pathway. Many proteins involved in the IL-12 pathway are also
involved in the IL-23 pathway, including IL-12p40 and Jak2. Our study indicates that geneti-
cally determined low IL-12p40 level (a subunit of both IL-12 and IL-23) was associated with
increased risk of CD (rs6887695), in accordance with other studies [25,26]. It could be specu-
lated, that a lower level of the IL-12p40 subunit results in a lower activity of the IL-12 pathway,
lower inactivation of the pro-inflammatory cytokine IL-17 and thus increased inflammatory
response, which might explain the increased risk of CD.
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Overall, the polymorphism in TLR5 (rs5744174) and IL12B (rs6887695) associated with
CD, the polymorphism TLR1 (rs4833095) and IL18 (rs187238) associated with both CD and
UC support that genetically determined high inflammatory response is associated with
increased risk of both CD and UC. In addition, the polymorphism in IL12B (rs6887695) associ-
ated with CD and the polymorphism in IL18 (rs187238) associated with both CD and UC sug-
gest that genetically determined high activity of the IL-23/IL-17 pathway was associated with
increased risk of CD and UC. It could be speculated that IL-17 plays a key role as IL-17 can be
inhibited by the IL-12 pathway and induced by the IL-23 pathway.
Studies have shown that mice deficient in the IL-23 pathway specific subunit (IL-23p19) or
subunits shared with IL12 (IL-12p40 and IL12R-β1) were resistant to inflammation, whereas
mice deficient in IL-12 pathway specific subunits (IL-12p35 and IL12R-β2) were more suscepti-
ble to inflammation [14]. Antibodies targeting the shared subunit IL-12p40 (Ustekinumab) have
been shown to be more effective than placebo in treating patients with severe CD, especially
those who failed to respond to anti-TNF therapy [37]. Based on our results it could be specu-
lated, that a better result might be obtained by using antibodies targeting the IL-23 specific sub-
unit IL-23p19, as our study indicates a protective effect of IL-12p40 through the IL-12 pathway.
The results in this study should be interpreted with care. TLR1 743 T>C (rs4833095) was
not in Hardy-Weinberg equilibrium among the healthy controls, which is probable due to
Fig 1. Eighteen functional single nucleotide polymorphisms (SNPs) in 14 genes were successfully genotyped and 4 SNPs in 4 genes were found
to be associated with susceptability of severe Crohn’s disease (CD), ulcerative colitis (UC) or combined CD and UC. The genes are involved in the
Toll-like receptor (TLR1 and TLR5) and the IL-23/IL-17 (IL12B and IL18) pathways. Other studies have also found the IL12BG>C (rs6887695) polymorphism
to be associated with risk of CD and our results confirm it as a risk locus. The TLR1 743 T>C (rs4833095)) polymorphism is a novel susceptibility loci.
doi:10.1371/journal.pone.0145302.g001
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chance. When corrected adequately for multiple testing no deviation from Hardy-Weinberg
equilibrium was found. In the light of the obtained P-values and the number of statistical tests
performed we cannot exclude, that some of our positive findings may be due to chance. If the
results were corrected for multiple testing the homozygous variant genotype of TLR1 743 T>C
(rs4833095) was associated with increased risk of CD (p = 0.02) and marginally with UC
(p = 0.07) and the combined homozygous and the heterozygous variant genotypes of IL12B
G>C (rs6887695) were marginally associated with increased risk of CD (p = 0.08). We success-
fully assessed 18 polymorphisms and assuming a 5% acceptance level, one polymorphism
would be expected to be associated with susceptibility by pure chance. In this study 5 polymor-
phisms were found to be associated with susceptibility and most of the found associations were
biologically plausible. We cannot exclude that associations were not identified due to insuffi-
cient statistical power. The results should therefore be replicated in independent cohorts. A
major strength was that this clinically homogeneous and well-characterised cohort was rather
large including 1035 patients with IBD and 795 healthy controls. All the patients were consid-
ered for anti-TNF treatment and were therefore considered to have a severe disease course.
Genetic determinants may be expected to be strong among severely ill cases [38].
In conclusion, 4 functional SNPs in 4 genes involved in regulation of inflammation
were found to be associated with susceptibility of severe CD or UC. The SNP in TLR1 743
(rs4833095) has not previously been reported as susceptibility polymorphisms of both CD
and UC (Fig 1). The IL12B G>C (rs6887695) polymorphism associated with risk of CD
in our study has also been associated with risk of CD in other studies and should therefore
be considered a confirmed risk locus. Our results suggest that genetically determined high
activity of TLR1 and TLR5 was associated with increased risk of CD and UC. This supports
that the host microbial composition or environmental factors in the gut are involved in
risk of IBD. Furthermore, genetically determined high activity of the IL-23/IL-17 pathway
was associated with increased risk of CD and UC. Overall, our results support that genetically
determined high inflammatory response was associated with increased risk of both CD
and UC.
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